


# WE LEVERAGE PROFOUND KNOWLEDGE OF BIOLOGY AND IMMUNO-ONCOLOGY FOR PRECISION CANCER TREATMENTS

Ymmunobio was founded in 2021 with the specific intent to develop drugs for hard to treat cancers and improve standard of care.

## PROBLEM STATEMENT – GASTROINTESTINAL CANCER



1 IN 2 CANCERS ARE GI CANCERS



1 IN 5 PATIENTS RESPOND TO AVAILABLE THERAPY (E.G. IN HCC)




1 IN 2 DEATHS THROUGH CANCER CAUSED BY GI CANCERS

## YMMUNOBIO HAS TWO PRODUCTS IN THE PIPELINE THAT WILL HELP PATIENTS SURVIVE GI CANCERS




**YB-200**, an anti CEACAM1/5 antibody works in immune sensitive and resistant tumors in HCC:


Janicot M et al. 2022 *J Immunotherapy of Cancer* 10 (Suppl 2) A1436



IMMUNE RESISTANT



IMMUNE SENSITIVE



aPD1



YB-200

### HEPATOCELLULAR CARCINOMA

100% Response to YB-200 in hot and cold tumors compared with Checkpoint Inhibitors which work only in 20% of cases (hot tumors)

### RESULTS PRESENTED AT SITC 2022 AND CIMT 2023

With this syngeneic mouse model, Ymmunobio achieved Proof of Principle and submitted an application for orphan drug designation in HCC which was granted by FDA in February 2023



**YB-800** is currently tested in different GI cancers on MoA and the possibility of ADC development. YB-800 binds to tumor cells alone, healthy tissue not affected.



### INTELLECTUAL PROPERTY

Both patents in country phase at the moment, i.e. EP, CHN, JPN, USA, HK  
Composition of matter & Method of use

Filing date **YB-200**: 10 MAY 2021 & **YB-800**: 25 JAN 2019

## ACCOMPLISHMENTS

- ✓ Purchase of both patents: YB-200 & YB-800
- ✓ Fully humanized monoclonal Antibodies
- ✓ Established Preclinical Proof of Principle for YB-200
- ✓ Presented results at SITC 2022 & CIMT 2023
- ✓ Granted Orphan Drug Status in HCC by USFDA for YB-200 (Feb 2023) on preclinical data.

## SOLUTIONS AND LEAD ASSETS

- ✓ **YB-200 novel dual mechanism of action**, proven efficacy in HCC (syngeneic mouse model) and orphan drug designation granted by FDA; HCC currently 6<sup>th</sup> most common cancer globally anticipated to grow by 55% until 2040 driven by Alcohol and Obesity/fatty liver.
- ✓ **YB-800 first-in-class antibody**, targeting NPTXR present on GI tumors. Healthy tissue not affected.

## MARKET SIZE IN 2027

HCC – second line \$2.4B market

CRC – third line \$3.0B market

## MANAGEMENT TEAM

**Peter Schiemann** | PhD, CEO & Chairman  
Entrepreneur with over 30 years experience in Parma

**Angela Gibbs** | MBA, CBO  
Over 25 years experience in Business Development

**Michel Janicot** | PhD, CDO  
Over 30 years experience in Drug Development and Preclinical Oncology



www.ymmuno.bio

Ymmunobio develops novel and first-in-class therapies for GI cancers, with the potential to capture a share of \$1.2B for each asset.


## MARKET OVERVIEW

**YB-200** lead indication is HCC. Today, only 1<sup>st</sup> line treatments are available for HCC, no 2<sup>nd</sup> line treatment option for patients failing 1<sup>st</sup> line, which are ~80%.

**YB-800** lead indication is CRC with currently a first and second line treatment available, but no third line.


### GLOBAL HCC MARKET

\$7.4 B → \$2.4 B → \$1.2 B  
2023 → 2<sup>nd</sup> line market → YB-200



### GLOBAL CRC MARKET

\$16.6 B → \$3 B → \$1.2 B  
2027 → 3<sup>rd</sup> line market → YB-800




## FUNDRAISING

Over \$1.4M has been raised by founders (500K) and individual investors to date.

Raising \$8M for Series A to achieve IND approval stage for the lead compound.

Series B: \$50M planned to achieve Proof of Concept in Humans.



## ROI

Current pre-money valuation @ \$10M; anticipated valuation @ IND approval: \$30M; @ PoC in Humans: \$200M.

Anticipated ROI (conservative) @ 10% Royalties: 30+ times investment p.a. for **YB-200** in HCC

## COMPANY BACKGROUND

Ymmunobio was founded in 2021 based on discoveries from Dr. Bernhard B Singer, Charité, Berlin, Germany and Dr. Mitsuro Kanda, Nagoya University, Japan. The Company is incorporated in Switzerland and the USA applying a virtual pharma business model.

Ymmunobio supported by **Innosuisse** – the Swiss incubator for start-up companies.

## SCIENTIFIC ADVISORS

**Katrin Rupalla** | PhD, MBA  
Founder & Drug Development Expert in Oncology; Global Head Regulatory @ J&J

**Prof. Iris Helfrich** | PhD  
Scientific Advisor  
Expert in experimental Dermato-Oncology, advisor on Melanoma studies

**Prof. Lopa Mishra** | MD  
Scientific Advisor  
Expert in GI cancer treatment; Commitment for Ph I study

**Prof. Keith Skubitz** | MD  
Scientific Advisor  
Expert in Hematology, Oncology & Transplantation; Co-inventor of the CD (clusters of differentiation) system

**Mitsuro Kanda** | MD  
Scientific Advisor and YB-800 inventor  
Surgeon for GI cancers, specialization on Gastric and Esophageal Cancer

**Martin E Zuzulo** | R&D Advisor  
Over 30 years of experience in several roles in the pharma and consulting industry

**Kenneth Yamashita** | CMC Expert  
Over 30 years of experience in Biologics Manufacturing

## BOARD OF DIRECTORS

**Peter Schiemann** | PhD  
Chairman  
Serial entrepreneur and Drug Development Expert. Founded 9 companies in the past 12 years

**Juergen Heitmann** | PhD  
NED  
Experienced BD Expert with experience in Pharma, VC and start-up companies, accompanied many major business transactions

**Caroline Germa** | MD  
NED  
Physician with over 25 year of experience in early oncology drug development

### CONTACT

**Dr. Peter Schiemann**  
CEO  
+1 908 294 1212  
peter.schiemann@ymmunobio



www.ymmunobio